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dDepartment of Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, NY, USAAbstract Introduction: Developing biomarkers that distinguish individuals with Alzheimer’s disease (AD)There were no con
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license (http://creativefrom those with normal cognition remains a crucial goal for improving the health of older adults.
We investigated adding brain spatial information to temporal event-related potentials (ERPs) to in-
crease AD identification accuracy over temporal ERPs alone.
Methods: With two-step principal components analysis, we applied multivariate analyses that incor-
porated temporal and spatial ERP information from a cognitive task. Discriminant analysis used tem-
porospatial ERP scores to classify participants as belonging to either the AD or healthy control group.
Results: Temporospatial ERPs produced a cross-validated area under the curve of 0.84. Adding
spatial information through a formal procedure significantly improves classification accuracy.
Discussion: Aweighted combination of temporospatial ERPmarkers performs well in detecting AD.
Because ERPs are noninvasive and inexpensive, they may be promising biomarkers for AD that can
add functional information to other biomarker systems while providing the individual’s probability of
correct classification.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Discriminant analysis; Brain event-related potentials (ERP); Electrophysiology; Alzheimer’s disease (AD);Aging; Principal components analysis (PCA); Receiver-operating characteristic (ROC); Posterior probabilities;
Two-step PCA; Temporospatial ERPs; Diagnosis; Brain spatial information; Temporal ERP components1. Introduction
Alzheimer’s disease (AD) is a persistent degenerative
neurological disorder with primary cognitive deficits in the
memory domain and whose impact is rising drastically [1].
Definitive diagnosis of AD was only possible postmortem
until recent advances in the design and refinement of bio-
markers. These biomarkers, which are typically based on
the molecular and neuroanatomic pathology of AD, have
had a major impact on the clinical assessment of AD inflicts of interest regarding this research.
thor. Tel.:1(585) 275-8679; Fax:1(585) 271-3043.
c@cvs.rochester.edu
/j.dadm.2018.08.002
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).living patients [2]. However, functionally these markers do
not adequately differentiate between the effects of normal
aging and the degeneration seen in AD. This nonspecificity
is further compounded by the fact that there is no biomarker
that reliably and robustly correlates with actual clinical,
cognitive decline in AD.
Cognitive brain event-related potentials (ERPs) have
been shown to detect AD in individuals [3]. Along with
behavioral methods, ERPs can give precise neurophysiolog-
ical bases for cognitive processes, including perception and
memory, which are adversely affected in AD [4,5]. In both
clinical and research settings, ERPs offer higher temporal
resolution compared to other brain imaging methods
in that they can detect electrophysiological changesimer’s Association. This is an open access article under the CC BY-NC-ND
Table 1
Demographic and behavioral results for healthy control and early-stage AD
groups with t-tests for significant differences between groups
Characteristics Alzheimer’s disease Healthy control P-value
Age 74.9 (7.4) 74.2 (7.1) NS
Education 14.4 (2.9) 15.5 (2.4) NS
MMSE* 24.6 (2.7) 29.1 (0.9) ,0.01
% Correct on ERP tasky 91.2 (15.7) 99.0 (1.8) ,0.0001
Abbreviations: AD, Alzheimer’s disease; ERP, event-related potential.
NOTE. Values appear as mean (SD) unless otherwise indicated. The age
and education information is in number of years. AD and healthy control
groups each contained 18 women and 18 men, totaling 36 participants.
*MMSE5Mini-Mental State Examination [11] (maximum of 30 points,
where higher scores indicate greater cognitive functioning). Neuropsycho-
logical test results are in Supplementary 1.
yNumber of correctly answered trials divided by the total number of trials
(204) in our number-letter paradigm (median [interquartile range]). Only
correct trials were used in subsequent ERP analyses.
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often developed without a formal, mathematical method of
combining temporal and spatial information. Adding
spatial information to temporal ERP measures may
increase their ability to identify AD. There are few
systematic ways to combine temporal and spatial
properties without arbitrary assumptions. ERPs are by
nature multivariate measures [6]; therefore, simplistic
measuring tools may not suffice to incorporate the richness
of information about the temporal properties of an ERP
waveform and its distribution over the scalp. New statistical
approaches that build upon previous work [7–10] effectively
combine temporal and spatial brain ERP properties formally
and mathematically, but these approaches have not yet been
applied to the development of biomarkers for AD where
reducing the number of possible predictors while
encompassing their most salient information is key. In
addition, because ERPs are inexpensive and noninvasive to
participants, improving their utility as a clinical tool to
assess functional changes related to AD is of great interest.
This study investigates if the multivariate addition of
brain spatial information to temporal ERP components im-
proves classification of early-stage AD by building upon pre-
vious work that identified individuals with AD using a single
electrode [3]. We gathered data from participants with early-
stage AD and cognitively normal older adults using a cogni-
tive/perceptual paradigm known to elicit ERPs representa-
tive of the cognitive processes typically affected by AD.
We then identified clinically usable ERP measures for AD
by applying multivariate analyses that incorporated both
temporal and spatial information into useful composite mea-
sures. These temporospatial ERPmeasures performwell in a
cross-validated discriminant analysis with a receiver-
operating characteristic (ROC) area under the curve (AUC)
of 0.84 and may represent a step toward establishing ERPs
as functional measures of cognitive decline that can poten-
tially enhance other biomarkers.
2. Methods
2.1. Study participants
We studied 36 elderly individuals diagnosed with early-
stage AD and 36 like-aged healthy controls (Table 1). These
72 participants were recruited from the Memory Disorders
Clinic at the University of Rochester and other affiliated
clinics. All AD participants were evaluated by memory-
disorder physicians and met established clinical criteria for
AD (National Institute of Neurological and Communicative
Disorders and Stroke and Alzheimer’s Disease and Related
Disorders Association, NINCDS-ADRDA) [1] and DSM-4
TR (Diagnostic and Statistical Manual of Mental Disorders,
4th edition, Text Revision) criteria for Dementia of the Alz-
heimer’s Type [12] and were considered early in the course
of the disease (see Supplementary Table 1). The memory
disorders physicians, who were blind to our ERP study
data, based their assessments on patient history, relevant lab-oratory findings, neuropsychological testing, and imaging
studies routinely performed as part of a comprehensive clin-
ical assessment of dementia. Healthy control participants
were cognitively normal for their age and demographically
similar to the AD participants (Supplementary Table 1).
Most healthy control participants were selected from the
Memory Disorders Clinic and underwent the same clinical
assessment for cognitive impairment. Some healthy control
participants were volunteers from the community and were
evaluated with a comprehensive neuropsychological test
battery designed to assess memory impairment.
There were no significant group (AD and healthy control)
or gender differences for age and education (Table 1).
Thirty-four of the 36 participants in the AD group were tak-
ing cholinesterase inhibitors to treat mild AD (one man and
one woman were not). All elderly participants had a clini-
cally administered score of 19 or higher on the MMSE
[11] (AD group mean 5 24.6). Exclusion criteria for all
elderly groups included clinical (or imaging) evidence of
stroke, Parkinson’s disease, HIV/AIDS, and reversible de-
mentias, as well as treatment with benzodiazepines, antipsy-
chotic, or antiepileptic medications. Our study was
conducted under IRB approval from the University of Ro-
chester Research Subjects Review Board, and informed con-
sent was obtained from each participant.
2.1.1. Neuropsychological assessment
Each participant was administered a comprehensive neu-
ropsychological test battery (Supplementary Table 1, has 29
scores) to assess cognitive processes impacted in AD and
memory disorders. As expected, the healthy control group
typically performed significantly better than the AD group
did. Of note, the Geriatric Depression Scale [13] did not
differ significantly between the groups, and no scores were
indicative of active depression. Also, the two groups did
not differ significantly on the American version of the Adult
National Reading Test (AMNART) [14], suggesting compa-
rable levels of verbal intelligence. Because our AD group
was generally early in the course of the disease, there was
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[15,16] that assesses functional capacity.
2.2. The number-letter paradigm
In our number-letter task [3,17,18], the intratrial stimulus
sequence contains two single-digit numbers (randomly
selected from 1 to 6) and two letters (randomly selected
from A to F) with these four stimuli flashed in random order
at fixed 750-ms intervals (intratrial parts). On a number-
relevant block of trials, the participant compared the two
numbers in each trial for numerical order, the letters being
irrelevant to the task. On a letter-relevant block of trials,
the participant compared the two letters in each trial for
alphabetic order, and the numbers were irrelevant to the
task. Importantly, memory storage of the first relevant stim-
ulus, which randomly appeared in intratrial part 1 or 2, was
required to compare it with the second relevant stimulus,
which randomly appeared in part 3 or 4. For more informa-
tion, see the Supplementary Materials and Supplementary
Fig. 1.
The number-letter task permits examination of ERPs in
response to 16 varying task conditions: two task relevancies
(relevant, irrelevant), two stimulus types (letters, numbers),
and four intratrial stimulus times (called intratrial parts).
2.3. Participant performance on the number-letter task
All participants were capable of performing the number-
letter task (on average both groups had greater than 90% accu-
racy [Table 1]). The healthy control group significantly outper-
formed theAD group (medians of 99.0% and 91.2% correct,F
[1,70]5 39.30,P,.0001). Therewasnomain effect of gender
or group by gender interaction on number-letter task perfor-
mance.Using behavioral task performance alone as a predictor
of dementia produced a sensitivity of only 0.58.
2.4. EEG recording
Scalp electrodes (a subset of the 10/20 electrodes
including O1, O2, OZ, T3, T4, T5, T6, P3, P4, PZ, C3,
C4, CZ, F3, F4, and left outer canthus for electrooculogram
(EOG) with reference to linked earlobes) were used to non-
invasively record electrical brain activity while the partici-
pant performed the number-letter task. The EOG detected
blinks and eye movements (see the Supplementary
Materials for more information). Mean artifact rejection
rate for the healthy control group was 10.5% (SD 5 19.2)
and for the AD group was 8.6% (SD 5 13.6). There was
no significant difference in artifact rejection rate
[t(70) 5 20.49, P 5 .62].
2.5. Event-related potential components: Temporospatial
principal components analysis
We derived ERPs for each participant from his/her elec-
troencephalogram (EEG) vectors (155 time points per elec-trode for each stimulus) by averaging each vector separately
for each of the 16 task conditions in this experimental design
(plus the two blanks—see the Supplementary Materials) and
for each of the 16 electrodes. The topography of average
ERP waveforms for each group for relevant and irrelevant
task conditions appears in Supplementary Fig. 2.
Because the ERP itself is a multivariate observation (due
to its many post-stimulus time samples), we applied Varimax
Principal Components Analysis (PCA) [6,19–21] to identify
and develop operational measures of the ERP components.
Volume conduction in the brain suggests an additive ERP
model, which underlies the PCA process in extracting the
component structure [6]. PCA can be used to separate func-
tionally distinct events by forming weighted linear combina-
tions of the original measurements that capture most of the
relevant variance. Temporospatial PCA can be useful when
it is likely components overlap both in space and in time.
It also achieves a great deal of data reduction and removes
the need to preselect time zones of interest or particular elec-
trodes or scalp zones to study. Temporospatial PCA is a two-
step procedure [8].
We first submitted to a Varimaxed temporal PCA the ERP
data from the two groups of 36 AD and healthy control par-
ticipants (described in Section 2.1) and data from an addi-
tional group of 36 participants clinically diagnosed with
mild cognitive impairment (MCI) (see Supplementary
Materials for demographics and further discussion of these
additional participants, including their ERP waveforms).
We included this set of 36 MCI participants to solve for
ERP components that would be more generalizable to a
wider array of individuals [22,23] with varying cognitive
and memory capabilities. The component scores from
these MCI participants are not used in further analysis here.
The data matrix that entered the temporal PCA contained
155 variables (time points per epoch) and 31,104 cases (108
participants! 16 electrodes! [two task relevancy! two
stimulus types ! four intratrial parts] 1 two blanks). This
PCA was computed using a correlation matrix [24]. In the
temporal PCA, there were nine ERP temporal components
that accounted for 98% of the total variance (each compo-
nent accounted for . 0.5% of the variance itself). One
component represented an ocular-related artifact [25] that
is not discussed further.
To compute spatial factors in the second PCA step, we
submitted the component scores from the first step for
each individual and each experimental condition (rele-
vancy, intratrial part) for each of the eight temporal
ERP components. This was done by transforming the
data so that the electrode sites (which also have compo-
nent scores because they were scored during the temporal
step) became the variables and all the participants, condi-
tions, and temporal components became the observations
in the input matrix of this second step. After Promax rota-
tion, this process yielded spatial factors. For each tempo-
ral component, there were two spatial factors whose
Eigenvalues were greater than 1. In general, these two
R.M. Chapman et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 604-614 607factors accounted for between 59% and 79% of the total
variance and had an interfactor correlation between
0 and 0.07 (Supplementary Table 2).2.6. Discriminant analysis
The temporospatial ERP scores were retained for
discriminant analysis [26,27] to build a discriminant
function with weights that classifies participants as
belonging to either the AD or the healthy control group.
The linear discriminant function is composed of the sum
of the selected component scores, each weighted by their
contribution in differentiating the participant groups. Once
the variables are selected, linear discriminant functions,
which include appropriate weights for each variable, can
be computed and applied to each individual in the data set.
We performed a development set, where each of the 72
participants contributed to the creation of the discriminant
function. To test the reliability of our discriminant
functions, a jackknifed cross-validation was also performed.
In this analysis (commonly called a one-left-out validation),
unique discriminant functions were built for each individual
without using his or her data in any step of computing the
PCA steps in finding the factor structure and discriminant
analyses (choosing predictors and calculating discriminant
coefficients). These functions were then applied to that
omitted participant. This procedure is done for each partici-
pant in the set. Because the participant being classified does
not contribute to the development of the function that is
applied to that participant, this method achieves a “nearly
unbiased estimate” [26]. See the Supplementary Materials
for more information on how this analysis was conducted.
Discriminant analysis also provides the posterior proba-
bilities of group membership for each individual [3,28,29].
These were analyzed to determine the confidence in each
individual’s classification. None of the subjects in either
the AD or healthy control groups was a multivariate outlier.3. Results
The temporospatial components extracted from PCA
(Fig. 1) included well-known components, such as P3
[17,30–33], Contingent Negative Variation (CNV) [34],
C250 [24,31,35,36], and other short- and long-latency com-
ponents.
Spatial factors for each temporal factor are also shown in
Fig. 1. Each temporal factor had two spatial factors: one
loading on mostly anterior electrode sites and the other on
posterior sites. We found no spatial factors with striking lat-
erality differences for any of the temporal components.
The temporospatial PCA produced component scores for
each spatial factor for each temporal component. These
scores were further differentiated by the experimental condi-
tions: Relevancy (relevant, irrelevant) and intratrial part (1–
4). This led to a possible 128 temporospatial componentscores (eight experimental conditions! two Spatial Factors
! eight temporal components) per subject (case). While
temporospatial PCA performed a great deal of data reduc-
tion by extracting the most important dimensions in the
data set, we selected potential variables for the discriminant
analysis by choosing spatial factors and experimental condi-
tions to encompass a wide variety of data. Our aim was to
reduce the number of variables a priori to a ratio of approx-
imately six cases to one variable for the discriminant pro-
cess. In our selection process, which was guided by
previous work [3,24], we made certain each temporal
component was represented at least once as we have found
that the weighted combination of multiple temporal ERP
components is best for discriminating between groups.
Because each temporal component is orthogonal to each
other, the information each contributes to the discriminant
analysis is likely to be fairly independent.
After our selection, we submitted 13 temporospatial ERP
scores to a stepwise discriminant procedure to further reduce
the number of predictors based on the correlational and covar-
iant relationships among the set of predictors. It selected 11
scores as discriminators between the AD and healthy control
groups (Table 2). These included relatively short-latency
components (such as C200, C115, and C250) and longer-
latency components (such as C525, P3, and CNV). In addi-
tion, both anterior and posterior spatial factors were chosen.3.1. Discriminant analysis
The SAS DISCRIM procedure was used to calculate
discriminant coefficients for each predictor. Given the linear
discriminant functions it developed (Table 2), we applied
these sets of weighted predictors to each participant for clas-
sification as a member of the AD or healthy control group.
Note that the weights included positive and negative values.
The accuracy of these classifications was judged against the
gold standard, blinded independent clinical assessment
(described more thoroughly in the Methods). We first
applied the functions to the data used to develop them (the
development set) and calculated sensitivity (the capacity of
the test to detect AD in the population) and specificity (the
extent to which the test is specific to AD). We also produced
ROC curves and determined the AUC, which can be consid-
ered the probability of a correct classification (Fig. 2). Using
our temporospatial ERP measures, our development set pro-
duced an excellent classification success (c2 5 40.53,
P , .0001) with an AUC of 0.93, sensitivity of 0.88, and
specificity of 0.86. The jackknifed cross-validation (Fig. 2)
also performed well (c2 5 20.20, P , .0001), with
AUC 5 0.84, sensitivity 5 0.81, and specificity 5 0.72.3.2. Posterior probabilities
Fig. 3 illustrates an example of using the posterior prob-
abilities to provide a quantitative context to the binary
Fig. 1. ERP temporospatial components. Each of the seven ERP temporal components on the left are named either with its common designation (e.g., P3) or
based onmaximum poststimulus (ms) (e.g., C250). For easier interpretability, thesewaveforms have themetric restored (bymultiplying the vector of component
loadings with the vector of standard deviations at each time point and given a component score of 1 [6]). Therewere two spatial factors for each temporal compo-
nent: one distributed more anterior and one over posterior scalp locations; these topo maps show ERP temporospatial factor loadings. Red hues indicate more
positive factor loadings. Blue hues indicate more negative factor loadings. Abbreviation: ERP, event-related potential.
R.M. Chapman et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 604-614608diagnostic decision for each individual. We ordered each
participant by the probability of belonging to the AD group
as determined by our temporospatial ERP measures. Partic-
ipants extremely likely to be in the healthy control group (C)
had nearly 0% chance of being classified as AD; conversely,
participants extremely likely to be in the AD group (A) had
nearly 100% chance of being in the AD group. Participants
with a classification probability of 0.5 were equally likely to
be in either group. Themisclassifications (C2, A2) are indi-
cated and appear on the “wrong side” of the cutoff line.3.3. Temporospatial ERP measures versus measures from
a single electrode
Compared to using a single electrode [3], the addition of
spatial information importantly improves the classification re-
sults (Fig. 4).We assessed this by computing the same discrim-
inant analysis without the second spatial PCA step. Instead,
only temporal ERPmeasures for CZ (the central midline elec-
trode, which, due to volume conduction, is reflective of neigh-
boring brain activity) entered the discriminant function. Using
Table 2
Linear discriminant function for discriminating between the AD and healthy control groups using temporospatial ERP scores
Temporal ERP component Spatial factor Experimental conditions
Discriminant coefficients
AD HC
C200 Posterior Parts: mean of 1, 2, 3, 4
Relevance: REL-IRR
20.94 12.45
C525 Posterior Parts: mean of 3 and 4
Relevance: REL
20.46 10.74
C250 Posterior Part: 1
Relevance: REL
21.62 10.40
P3 Posterior Parts: mean of 1, 2, 3, 4
Relevance: mean of REL, IRR
20.68 10.55
C115 Posterior Parts: mean of 2 and 4
Relevance: REL
10.61 20.50
C250 Anterior Part: 1
Relevance: REL
20.48 10.35
C160 Anterior-Posterior Parts: mean of 1, 2, 3, 4
Relevance: mean of REL, IRR
20.43 10.18
CNV Posterior Part: mean of 2 and 4
Relevance: IRR
10.82 10.16
C250 Posterior Parts: mean of 1, 2, 3, 4
Relevance: IRR
11.92 20.15
P3 Anterior Parts: mean of 1, 2, 3, 4
Relevance: REL
20.79 10.69
C200 Anterior Parts: mean of 1, 2, 3, 4
Relevance: REL-IRR
20.59 22.03
Constant 20.70 20.91
Abbreviations: AD, Alzheimer’s disease; ERP, event-related potential; HC, healthy controls.
NOTE. The stepwise discriminant procedure selected the 11 temporospatial scores listed above for the development set. These included measures from most
temporal components and from both spatial factors (anterior and posterior). In addition, a variety of experimental conditions are represented. The weights
(discriminant coefficients) are applied to each measure for each discriminant function (AD or healthy control). The weighted measures are summed and added
to the constant to produce an AD and healthy control result for each participant. These resultant sums are then used to determine group membership (Fig. 3).
Parts refer to intratrial parts and relevance refers to task relevancy within a number-letter trial.
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mental conditions to keep these aspects constant, we found,
without the addition of empirically derived spatial informa-
tion, the development analysis performedwith only 74%accu-
racy on this same set of participants.This is in comparisonwith
88% accuracy using temporospatial measures (Fig. 2). The
cross-validation accuracy was also markedly reduced for the
single-electrode analysis to 61% from 76% in temporospatial
analysis. Both of these single-electrode results are significantly
less accurate than the same analysis performed with our tem-
porospatial markers (development: c2 5 5.22, P , .05,
cross-validation: c25 3.82, P, .05).
4. Discussion
Temporospatial ERP measures provide a concise, consol-
idated method of representing salient information about
brain activity related to information processing. Our two-
step PCA approach reduced a large amount of continuous
data in both temporal and spatial domains to discrete mea-
sures easily attributable to experimental conditions.
Discriminant analysis weighted these measures to differen-
tiate between AD and healthy control individuals while
providing a key quantitative context to that decision by pos-
terior probabilities of group membership.4.1. Posterior probabilities
Using the posterior probabilities provided by the discrimi-
nant function, we can separate the classifications that may be
borderline or “too close to call” (Fig. 3). This can help identify
individuals with confidentAD classifications.Using a range of
0.40 to 0.60, eight of the 72 participants appeared in the “too
close to call” area. More importantly, 64 of the 72 participants
(89%)had posterior probabilities outside the “too close to call”
range, and 80% of those participants were correctly classified.
These classification probabilities based on temporospatial
ERP measures may add important information to a clinical
diagnosis. The temporospatial ERP test misclassified 10
healthy control participants as AD, but perhaps these errors
could be construed as predictions of AD (Fig. 3). The probabil-
ity of AD diagnosis based on temporospatial ERP measures in
an individual with clinically normal cognition might reflect
early AD pathophysiology that has not reached clinical signif-
icance. This information regarding high likelihood of future
phenoconversion toADmay improve early detection and guide
a physician in determining pre-emptive treatment strategies. It
also may aid researchers in identifying appropriate participants
for preclinical trials where therapies are designed to prevent or
slow phenoconversion to clinically manifest AD, potentially
increasing the likelihood of these therapies’ success.
Fig. 2. ROC curves for the development and cross-validation analyses using temporospatial ERP measures to compute the discriminant functions. The devel-
opment analysis involved applying the discriminant functions to the data (participants) used to develop them. The one-left-out (or jackknifed) cross-validation
was performed by omitting one participant when developing the PCA structure, selecting the measures, and creating discriminant functions. The discriminant
functions were then applied to the omitted participant. This was done for each participant. Area under the curve (AUC) has a maximum value of 1. Sensitivity is
calculated as the number of correctly classified AD participants divided by the total number of AD participants (or true positives/[true positives 1 false neg-
atives]). Specificity is calculated as the number of correctly classified healthy control participants divided by the total number of healthy control participants (or
true negatives/[true negatives1 false positives]). Abbreviations: AD, Alzheimer’s disease; ERP, event-related potential; PCA, principal components analysis;
ROC, receiver-operating characteristic.
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Fig. 3. Posterior probabilities for each of the 36 individual classifications belonging to the AD or healthy control group (cross-validation). A probability of 1.0
indicates complete likelihood of belonging to the AD group, 0.5 indicates the participant is equally likely of being placed in the AD or healthy control group, and
0 indicates complete likelihood of belonging to the healthy control group. Misclassified individuals are marked (2). Participants are ordered by their probability
(with the most confident probabilities of an AD or healthy control diagnosis shown to the left). Those in the gray area labeled “too close to call” have prob-
abilities too close to chance to make a confident classification. Abbreviation: AD, Alzheimer’s disease.
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neurodegeneration
While many studies have investigated one or perhaps two
ERP measures as discriminators of AD, we posit that the
weighted contribution of many ERP measures may produce
a more complete picture of degenerating brain activity
and reflect the involvement of large distributed networks
supporting cognitive function. In addition, with the use of
temporospatial PCA, we can identify the most salient infor-
mation from both the temporal waveforms and spatial distri-
butions without threatening the degrees of freedom in the
discriminant analysis. This is a key facet of our analysis,
as our composite ERP measures can encompass the most
important temporal, spatial, and cognitive data.
Clearly a multivariate approach to using ERPs as
markers of AD is important. We have first demonstrated
that a weighted combination of different ERP markers
performs well as a system of identifying individuals
with AD. Second, the addition of spatial information
through a formal, multivariate procedure improves the
classification accuracy (P , .05 for both development
and cross-validation analyses). Spatial data could be
included through averaging, but a two-step temporospa-
tial PCA provides for data reduction while including the
most salient information and, importantly, does not rely
on assumptions about the spatial structure of the
components.4.3. Implications
Because ERPs are indices of brain electrophysiological
activity with high temporal resolution, they may be able to
add important functional information about cognitive pro-
cesses that other biomarkers cannot easily provide. The re-
sults presented here are a step toward more challenging
clinical questions of predicting preclinical AD and providing
functional cognitive measures that can enhance other bio-
markers. Further research is essential to relate these ERP
biomarkers to other biomarkers, such as cerebrospinal fluid
(CSF) biomarker signatures, blood biomarkers, and imag-
ing. Recent work using CSF markers showed a comparable
ROC AUC of 0.86 in classifying AD and healthy elderly us-
ing a comparable number of participants [37]. While our
sample sizes are ample, a larger number of participants
would permit further validation of the generalizability and
reliability of the discriminant functions through applying
these discriminant functions to an independent test set of
participants. Also, longitudinal studies are warranted in pre-
clinical AD individuals to assess the predictive value of our
ERP measures, particularly in MCI individuals with high
amyloid load or with positive blood lipid markers for demen-
tia [38]. Because ERPs offer functional data concerning
brain activity with high temporal resolution, they hold prom-
ise as a biomarker system that can enhance and possibly
improve the detection of AD in older adults with reasonable
probability of accurate classification.
Fig. 4. ROC curves for the development and cross-validation analyses using ERPmeasures from a single electrode (CZ) to compute the discriminant functions.
See Fig. 2 for more description of the process used to derive these results and a comparison with discriminant results using temporospatial ERP scores. Abbre-
viations: ERP, event-related potential; ROC, receiver-operating characteristic.
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1. Systematic review: Most Alzheimer’s disease (AD)
biomarker research involves biochemical and/or
structural measures rather than identifying functional
measures related to varying cognitive processes.
Brain event-related potentials (ERPs), which are
inexpensive and noninvasive, show promise as
functional biomarkers. However, combining spatial
and temporal ERP information has not yet been at-
tempted in AD biomarker research.
2. Interpretation: We investigated the classificatory per-
formance of combinations of brain ERPs in individ-
uals with AD and age-matched cognitively healthy
controls.We expanded the use of ERPs to incorporate
both temporal and spatial information through two-
step principal components analysis. Our approach
includes a quantitative measure (posterior probabil-
ity) for each individual’s classification. These novel
ERP biomarkers performed with excellent accuracy
in classifying early-stage AD and healthy controls,
confirmed with significant cross-validation.
3. Future directions: Longitudinal analyses are warranted
in preclinicalAD individuals to investigatewhether this
ERPbiomarker approachmay aid in disease prediction.References
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